PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION. (23rd June 2022) - Gore, L.; Loh, M.; Pui, C.-H.; Matloub, Y.; Hanley, M. J.; Du, J.; Hennessy, M.; Granier, M.; Biondi, A.; Silverman, L.